Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • HOME

      RINVOQ AD

      HUMIRA

      SKYRIZI

      SKINVERSATIONS

      SERVICES

      CONTACT

      Humira logo
      About HUMIRA
      Presentation & Dosing
      Services
      Resources

      Over 20,000 Australian patients currently use HUMIRA.#6

      Why do you choose HUMIRA?

      #As of January 20236

      Redesigned Pen infographic
      Safety Data Infographic

      Extensive safety data collected from ~30,000 patients in more than 77 global clinical studies, across 10 indications.7

      Redesigned pen infographic

      Dedication to patient-centric innovations such as the HUMIRA citrate-free formulation, 80 mg presentation and redesigned Pen.2,4,5,8

      Storage sites infographic

      Reliable patient access to HUMIRA, supported by multiple manufacturing and storage sites.9

      No additional cost infographic

       

      to your patient (vs adalimumab biosimilars)10,11
      §HUMIRA does not attract a brand premium10,11

      Contact a rep
      Contact a rep

      More for you

      Click to view
      AbbVie Care

      How to enrol your patients on HUMIRA

      SKYRIZI
      SKYRIZI

      Learn more

      Skinversations
      Skinversations

      The latest on all things dermatology

      PBS Information

      Humira: Authority required. Refer to PBS Schedule for full authority information. This product is not listed on the PBS for the treatment of enthesitis-related arthritis, paediatric psoriasis or uveitis.

      Please review the full Product Information (PI) before prescribing, available below.

      HUMIRA PI

      OLE: open label extension. OR: observational registry. PBS: Pharmaceutical Benefits Scheme. RCT: randomised controlled trial.

      References: 1. AbbVie Data on File. CLA-AU-210006. 2. Australian Government. Department of Health. The Pharmaceutical Benefits Scheme. Adalimumab Pharmaceutical Benefits Scheme changes - 1 April 2021. Available at pbs.gov.au/news/2021/03/adalimumab-files/Adalimumab-biosimilar-PBS-changes-1-April-2021.pdf Accessed: April 2023. 3. Burmester GR et al. Ann Rheum Dis 2009;68(12):1863–9. 4. HUMIRA Product Information. 5. Nash P et al. Rheumatol Ther 2016;3(2):257–70. 6. AbbVie Data on File. CLA-AU-200032. 7. Burmester GR et al. Adv Ther 2020;37(1):364–80. 8. HUMIRA Consumer Medicine Information. 9. AbbVie Data on File. CLA-AU-220032. 10. Australian Government. Department of Health. Phamaceutical Benefits Scheme. PBS Schedule. Available at pbs.gov.au/pbs/search?term=adalimumab Accessed: April 2023. 11. Australian Government. Department of Health. Biosimilar uptake drivers. Available at pbs.gov.au/general/biosimilars/biosimilar-uptake-drivers-q-and-a.pdf Accessed: April 2023.

      AU-HUM-200081. June 2023